DRREDDY

Leading pharma major Dr Reddy's Laboratories is banking on a multi-pronged strategy to offset the price erosion of its top-selling generic for Revlimid, or lenalidomide, CFO MV Narasimham has said, which would include rollout of biosimilars, launch of weight loss drug Ozempic’s generics, aside of acquisitions and licensing deals. The patent for Revlimid, a major contributor to Dr Reddy's topline, is set to expire in US in January 2026, which would open the doors to more competition and revenue loss for the pharma company. The CFO added that Dr Reddy’s intends to launch semaglutide Ozempic’s generics in markets where patents are set to expire starting next calendar year. A semaglutide is an anti-diabetic drug used to treat type 2 diabetes and is an anti-obesity medication used for weight management. Lenalidomide, a generic drug, is an oral medication taken once a day to treat certain blood cancers.